trial
as of 2026-07-01Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia
NCTId NCT03503318
at a glance
Phase 3 · Completed
Enrollment 544 (actual)
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc.
Primary completion 2020-09-30
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
544 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2018-04-27
Primary completion
2020-09-30
Eligibility
ALL · 13 Years · 65 Years
Interventions & indications
Drugs
Indications
Sponsors
Teva Branded Pharmaceutical Products R&D, Inc.Lead Sponsor
Investigators
1
Teva Medical Expert, MDStudy Director
Sites
81 total
Little Rock, United StatesRogers, United StatesAnaheim, United StatesBellflower, United StatesColton, United StatesCosta Mesa, United StatesCosta Mesa, United StatesCulver City, United StatesGarden Grove, United StatesGlendale, United StatesLa Habra, United StatesLemon Grove, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
544
Phase
PHASE3
Primary Completion Date
2020-09-30
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
indication
indication
investigator
person